Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 6/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.42 |
| ▸ | PNP | P00491 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26288677 | 0.82 | AHCY (0.46) | AHCYCA5ANT5ELMNAHIF1A | |
| SCHEMBL25397841 | 0.82 | AHCY (0.46) | AHCYCA5ANT5ELMNAHIF1A | |
| SCHEMBL26268275 | 0.81 | AHCY (0.54) | AHCYCA5ANT5ELMNAHIF1A | |
| SCHEMBL26268274 | 0.80 | LMNA (0.61) | AHCYCA5ANT5ELMNAHIF1A | |
| SCHEMBL17131338 | 0.80 | AHCY (0.34) | AHCYCA5A | |
| SCHEMBL16178424 | 0.79 | AHCY (0.63) | AHCYCA5ANT5ELMNAHIF1A | |
| SCHEMBL16178422 | 0.79 | AHCY (0.63) | AHCYCA5ANT5ELMNAHIF1A | |
| SCHEMBL23897428 | 0.79 | AHCY (0.63) | AHCYCA5ANT5ELMNAHIF1A | |
| SCHEMBL7619845 | 0.79 | AHCY (0.59) | AHCYCA5ANT5ELMNAHIF1A | |
| SCHEMBL13529762 | 0.76 | AHCY (0.60) | AHCYCA5ANT5ELMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | AHCY 3405/4885CA5A 1251/4885NT5E 865/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | AHCY 3405/4885CA5A 1251/4885NT5E 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.